HK1016877A1 - Bioactivated diagnostic imaging contrast agents. - Google Patents
Bioactivated diagnostic imaging contrast agents.Info
- Publication number
- HK1016877A1 HK1016877A1 HK99101864A HK99101864A HK1016877A1 HK 1016877 A1 HK1016877 A1 HK 1016877A1 HK 99101864 A HK99101864 A HK 99101864A HK 99101864 A HK99101864 A HK 99101864A HK 1016877 A1 HK1016877 A1 HK 1016877A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- agents
- bioactivated
- contrast agents
- diagnostic imaging
- imaging contrast
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title abstract 2
- 238000002059 diagnostic imaging Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 2
- 238000012634 optical imaging Methods 0.000 abstract 2
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000011896 sensitive detection Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1444896P | 1996-04-01 | 1996-04-01 | |
PCT/US1997/004804 WO1997036619A2 (en) | 1996-04-01 | 1997-03-25 | Bioactivated diagnostic imaging contrast agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1016877A1 true HK1016877A1 (en) | 1999-11-12 |
Family
ID=21765541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK99101864A HK1016877A1 (en) | 1996-04-01 | 1999-04-27 | Bioactivated diagnostic imaging contrast agents. |
Country Status (19)
Country | Link |
---|---|
US (3) | US6709646B2 (zh) |
EP (1) | EP0907379B1 (zh) |
JP (2) | JP2000507577A (zh) |
KR (1) | KR20060025233A (zh) |
CN (1) | CN1108824C (zh) |
AT (1) | ATE268187T1 (zh) |
AU (1) | AU726914B2 (zh) |
BR (1) | BR9708470A (zh) |
CA (1) | CA2247620A1 (zh) |
DE (1) | DE69729380T2 (zh) |
DK (1) | DK0907379T3 (zh) |
ES (1) | ES2217408T3 (zh) |
HK (1) | HK1016877A1 (zh) |
IL (1) | IL125895A (zh) |
IS (1) | IS2059B (zh) |
NO (1) | NO319674B1 (zh) |
NZ (1) | NZ331629A (zh) |
PT (1) | PT907379E (zh) |
WO (1) | WO1997036619A2 (zh) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770261B2 (en) * | 1995-06-02 | 2004-08-03 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
US6713045B1 (en) | 1995-06-02 | 2004-03-30 | Research Corporation Technologies, Inc. | Targeted magnetic resonance imaging agents for the detection of physiological processes |
US5900228A (en) | 1996-07-31 | 1999-05-04 | California Institute Of Technology | Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye |
US6675035B1 (en) * | 1997-06-20 | 2004-01-06 | Imaging Diagnostic Systems, Inc. | Phantom for optical and magnetic resonance imaging quality control |
ATE254479T1 (de) * | 1997-10-02 | 2003-12-15 | Epix Medical Inc | Verfahren für verbesserte kontrast- bilderzeugung zur therapieüberwachung |
US6713046B1 (en) | 1997-10-27 | 2004-03-30 | Research Corporation Technologies | Magnetic resonance imaging agents for the delivery of therapeutic agents |
DE69811931T2 (de) * | 1997-10-27 | 2003-12-18 | Res Corp Technologies Inc | Mri-mittel für die verabreichung von therapeutischen mitteln |
AU752812B2 (en) | 1997-11-17 | 2002-10-03 | Research Corporation Technologies, Inc. | Magnetic resonance imaging agents for the detection of physiological agents |
IT1297035B1 (it) * | 1997-12-30 | 1999-08-03 | Bracco Spa | Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico |
IT1297034B1 (it) * | 1997-12-30 | 1999-08-03 | Bracco Spa | Acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico |
US6167297A (en) | 1999-05-05 | 2000-12-26 | Benaron; David A. | Detecting, localizing, and targeting internal sites in vivo using optical contrast agents |
US6230586B1 (en) * | 1999-05-21 | 2001-05-15 | Chung-Hsi Chang | Electric drive device for a bicycle |
NZ517017A (en) | 1999-07-29 | 2004-05-28 | Epix Medical Inc | Targeting multimeric imaging agents through multiocus binding and improving the efficacy of in vivo contrast agents |
JP2003520255A (ja) * | 2000-01-22 | 2003-07-02 | エピックス メディカル, インコーポレイテッド | 酵素的な切断によって生理活性化される造影剤プロドラッグを使用した磁気共鳴画像法 |
US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
US20040146463A1 (en) * | 2000-05-04 | 2004-07-29 | Meade Thomas J. | Functional MRI agents for cancer imaging |
WO2001082795A2 (en) * | 2000-05-04 | 2001-11-08 | Research Corporation Technologies | Magnetic resonance imaging agents for the delivery of therapeutic agents |
US6673333B1 (en) | 2000-05-04 | 2004-01-06 | Research Corporation Technologies, Inc. | Functional MRI agents for cancer imaging |
EP1283728A2 (en) * | 2000-05-23 | 2003-02-19 | Amersham Health AS | Contrast agents |
US6748259B1 (en) | 2000-06-15 | 2004-06-08 | Spectros Corporation | Optical imaging of induced signals in vivo under ambient light conditions |
US6656450B2 (en) | 2000-07-17 | 2003-12-02 | California Institute Of Technology, Inc. | Macrocyclic magnetic resonance imaging contrast agents |
WO2002028441A2 (en) | 2000-10-04 | 2002-04-11 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
US20030004236A1 (en) * | 2001-04-20 | 2003-01-02 | Meade Thomas J. | Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances |
WO2002087632A1 (en) * | 2001-05-02 | 2002-11-07 | Metaprobe, Inc. | High throughput screening methods using magnetic resonance imaging agents |
TWI221406B (en) | 2001-07-30 | 2004-10-01 | Epix Medical Inc | Systems and methods for targeted magnetic resonance imaging of the vascular system |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
EP1572724A4 (en) | 2002-03-01 | 2007-03-14 | Dyax Corp | KDR AND VEGF / KDR BINDING SPEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US20030198597A1 (en) * | 2002-04-22 | 2003-10-23 | Meade Thomas J. | Novel macrocyclic activatible magnetic resonance imaging contrast agents |
AU2003251436A1 (en) * | 2002-07-22 | 2004-02-09 | Bracco Imaging S.P.A. | Procedures of cellular labelling with paramagnetic complexes for mri applications |
US20050163821A1 (en) * | 2002-08-02 | 2005-07-28 | Hsing-Wen Sung | Drug-eluting Biodegradable Stent and Delivery Means |
US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
CA2517939C (en) | 2003-03-03 | 2015-11-24 | Dyax Corp. | Peptides that specifically bind hgf receptor (cmet) and uses thereof |
WO2005016141A1 (en) * | 2003-07-09 | 2005-02-24 | California Pacific Medical Center | Remote detection of substance delivery to cells |
US20050106100A1 (en) * | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
WO2005057169A2 (en) * | 2003-12-05 | 2005-06-23 | Trellis Bioscience, Inc. | Homogeneous competition assays |
NO20035683D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av prostatakreft |
FR2868320B1 (fr) * | 2004-03-31 | 2007-11-02 | Centre Nat Rech Scient Cnrse | Agent de contraste pour l'imagerie par resonance magnetique |
US20060204539A1 (en) * | 2005-03-11 | 2006-09-14 | Anthony Atala | Electrospun cell matrices |
US7531503B2 (en) * | 2005-03-11 | 2009-05-12 | Wake Forest University Health Sciences | Cell scaffold matrices with incorporated therapeutic agents |
US9248015B2 (en) * | 2005-03-11 | 2016-02-02 | Wake Forest University Health Services | Production of tissue engineered heart valves |
WO2006099372A2 (en) * | 2005-03-11 | 2006-09-21 | Wake Forest University Health Sciences | Tissue engineered blood vessels |
US20060204445A1 (en) * | 2005-03-11 | 2006-09-14 | Anthony Atala | Cell scaffold matrices with image contrast agents |
US8728463B2 (en) * | 2005-03-11 | 2014-05-20 | Wake Forest University Health Science | Production of tissue engineered digits and limbs |
WO2007005491A1 (en) * | 2005-06-30 | 2007-01-11 | Bristol-Myers Squibb Pharma Company | Hydrazide conjugates as imaging agents |
US9339559B2 (en) * | 2005-09-09 | 2016-05-17 | Georgia State University Research Foundation, Inc. | Targeted contrast agents and methods for targeting contrast agents |
EP1745739A3 (en) | 2005-07-14 | 2009-04-22 | Bundesrepublik Deutschland, vertr. d.d. Bundes- ministerium f. Wirtschaft- und Technologie, dieses vertr. d.d. Präs. d. Phys.-Techn. Bundesanstalt | Optical imaging of rheumatoid arthritis |
US20080058636A1 (en) | 2005-12-29 | 2008-03-06 | Epix Pharmaceuticals, Inc. | Methods of myocardial imaging |
EP3656403B1 (en) | 2007-08-17 | 2022-05-11 | Purdue Research Foundation | Preparation process of psma binding ligand-linker conjugates |
JPWO2009054327A1 (ja) * | 2007-10-22 | 2011-03-03 | 財団法人大阪産業振興機構 | Mri用プローブ |
US20120045393A1 (en) | 2009-03-17 | 2012-02-23 | Linder Karen E | Lhrh-ii peptide analogs |
AU2010226479A1 (en) | 2009-03-19 | 2011-09-22 | Wyeth Llc | Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) -en-2-yl)ethyl]phosphonic acid and precursors thereof |
WO2010121133A2 (en) | 2009-04-17 | 2010-10-21 | The General Hospital Corporation | Multimodal imaging of fibrin |
JP2011026294A (ja) | 2009-06-26 | 2011-02-10 | Canon Inc | 化合物 |
WO2011035140A1 (en) | 2009-09-18 | 2011-03-24 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of contrast moieties to the lungs |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
CN102188722A (zh) * | 2010-03-18 | 2011-09-21 | 中国科学院福建物质结构研究所 | 一种含二价铁的磁共振成像造影剂 |
US8192429B2 (en) | 2010-06-29 | 2012-06-05 | Theravant, Inc. | Abnormality eradication through resonance |
KR102057132B1 (ko) | 2012-03-08 | 2019-12-18 | 토멘 메디칼 아게 | 염증성 조직을 진단하기 위한 치과적 용도의 츄잉검 |
WO2013131994A2 (en) * | 2012-03-08 | 2013-09-12 | Thommen Medical Ag | Coating for the diagnosis of inflammatory tissues in dental applications |
JP6892218B2 (ja) | 2012-11-15 | 2021-06-23 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 薬物送達結合体およびpsma発現細胞によって引き起こされる疾患の治療方法 |
US10092679B2 (en) | 2013-10-18 | 2018-10-09 | Wake Forest University Health Sciences | Laminous vascular constructs combining cell sheet engineering and electrospinning technologies |
GEP20237496B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US20150344523A1 (en) | 2014-05-05 | 2015-12-03 | California Institute Of Technology | Mutant akt-specific capture agents, compositions, and methods of using and making |
WO2015196208A2 (en) | 2014-06-20 | 2015-12-23 | The General Hospital Corporation | Collagen targeted imaging probes |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
EP3270951B1 (en) | 2015-03-16 | 2020-09-09 | California Institute of Technology | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
WO2017011769A2 (en) | 2015-07-15 | 2017-01-19 | California Institute Of Technology | Il-17f-specific capture agents, compositions, and methods of using and making |
US20170319722A1 (en) | 2016-04-04 | 2017-11-09 | Indi Molecular, Inc. | Cd8-specific capture agents, compositions, and methods of using and making |
EP3519425B1 (en) | 2016-09-29 | 2024-02-28 | Indi Molecular, Inc. | Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same |
WO2018085375A1 (en) | 2016-11-01 | 2018-05-11 | Ohio State Innovation Foundation | Methods for the iodination of biomolecules |
CA3057976A1 (en) * | 2017-04-27 | 2018-11-01 | The Regents Of The University Of California | Modified mri contrast agents and uses thereof |
WO2018232345A1 (en) | 2017-06-15 | 2018-12-20 | Indi Molecular, Inc. | Il-17f and il-17a-specific capture agents, compositions, and methods of using and making |
US20210299158A1 (en) * | 2017-10-11 | 2021-09-30 | Northwestern University | Heparin Conjugated to Collagen-Binding Peptides for Targeting to Biological and Synthetic Tissues |
CN108314695B (zh) * | 2018-01-04 | 2020-06-16 | 南京邮电大学 | 一种异种双核金属配合物的制备及应用 |
US11919972B2 (en) | 2018-11-02 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Peptide libraries with non-canonical amino acids |
US11638764B2 (en) | 2018-11-08 | 2023-05-02 | Indi Molecular, Inc. | Theranostic capture agents, compositions, and methods of using and making |
WO2020186091A1 (en) | 2019-03-12 | 2020-09-17 | Indi Molecular, Inc. | Cross-linked epitopes and methods of use thereof |
WO2020236969A1 (en) | 2019-05-20 | 2020-11-26 | Indi Molecular, Inc. | Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1) |
US11414460B2 (en) | 2019-07-19 | 2022-08-16 | Institute For Systems Biology | KRAS-specific capture agents, compositions, and methods of making and using |
CN112891566A (zh) * | 2019-12-04 | 2021-06-04 | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 一种纳米材料及其制备方法和包含其的造影剂 |
AU2021265205A1 (en) | 2020-04-30 | 2023-01-05 | Academisch Ziekenhuis Groningen | Anti-CD103 antibodies |
WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
WO2022098745A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4899755A (en) | 1985-05-08 | 1990-02-13 | The General Hospital Corporation | Hepatobiliary NMR contrast agents |
US4880008A (en) | 1985-05-08 | 1989-11-14 | The General Hospital Corporation | Vivo enhancement of NMR relaxivity |
WO1988002635A1 (en) * | 1986-10-17 | 1988-04-21 | Cytogen Corporation | Method for preparation of protein-chelator-metal ion compositions suitable for injection |
US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
US5171563A (en) | 1988-09-30 | 1992-12-15 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
US5094848A (en) * | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
DE69032761T2 (de) * | 1989-08-28 | 1999-04-22 | Gen Hospital Corp | Hydroxy-aryl metallchelate für bildformung zur nmr diagnose |
USH1312H (en) * | 1992-05-28 | 1994-05-03 | Cytogen Corporation | Method for the preparation of gyk-dtpa |
WO1994008624A2 (en) * | 1992-10-14 | 1994-04-28 | Sterling Winthrop Inc. | Therapeutic and diagnostic imaging compositions and methods |
DE4341724A1 (de) * | 1993-12-03 | 1995-06-08 | Schering Ag | Halogenaryl-substituierte Metallkomplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel |
JPH09505819A (ja) * | 1993-12-03 | 1997-06-10 | ブラッコ エッセ.ピ.ア. | 核磁気共鳴診断用常磁性キレート |
TW319763B (zh) * | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
DE19507822B4 (de) * | 1995-02-21 | 2006-07-20 | Schering Ag | Substituierte DTPA-Monoamide der zentralen Carbonsäure und deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik und Therapie sowie Verfahren zur Herstellung der Komplexe und Mittel |
US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
US5707605A (en) | 1995-06-02 | 1998-01-13 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
-
1997
- 1997-03-25 CN CN97193542A patent/CN1108824C/zh not_active Expired - Fee Related
- 1997-03-25 PT PT97916974T patent/PT907379E/pt unknown
- 1997-03-25 DK DK97916974T patent/DK0907379T3/da active
- 1997-03-25 WO PCT/US1997/004804 patent/WO1997036619A2/en not_active Application Discontinuation
- 1997-03-25 EP EP97916974A patent/EP0907379B1/en not_active Expired - Lifetime
- 1997-03-25 DE DE69729380T patent/DE69729380T2/de not_active Expired - Fee Related
- 1997-03-25 BR BR9708470A patent/BR9708470A/pt not_active Application Discontinuation
- 1997-03-25 AT AT97916974T patent/ATE268187T1/de not_active IP Right Cessation
- 1997-03-25 JP JP9535373A patent/JP2000507577A/ja not_active Ceased
- 1997-03-25 KR KR1020067003261A patent/KR20060025233A/ko not_active Application Discontinuation
- 1997-03-25 IL IL12589597A patent/IL125895A/en not_active IP Right Cessation
- 1997-03-25 AU AU25448/97A patent/AU726914B2/en not_active Ceased
- 1997-03-25 ES ES97916974T patent/ES2217408T3/es not_active Expired - Lifetime
- 1997-03-25 CA CA002247620A patent/CA2247620A1/en not_active Abandoned
- 1997-03-25 NZ NZ331629A patent/NZ331629A/xx unknown
-
1998
- 1998-08-26 IS IS4833A patent/IS2059B/is unknown
- 1998-09-29 NO NO19984543A patent/NO319674B1/no unknown
-
1999
- 1999-04-27 HK HK99101864A patent/HK1016877A1/xx not_active IP Right Cessation
-
2001
- 2001-09-14 US US09/952,971 patent/US6709646B2/en not_active Expired - Fee Related
-
2004
- 2004-01-16 US US10/758,729 patent/US7147837B2/en not_active Expired - Fee Related
- 2004-02-27 JP JP2004055545A patent/JP2004210796A/ja active Pending
-
2006
- 2006-08-16 US US11/504,851 patent/US20060275216A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE268187T1 (de) | 2004-06-15 |
EP0907379A2 (en) | 1999-04-14 |
NO984543L (no) | 1998-11-26 |
BR9708470A (pt) | 1999-04-13 |
DK0907379T3 (da) | 2004-08-16 |
JP2000507577A (ja) | 2000-06-20 |
ES2217408T3 (es) | 2004-11-01 |
US7147837B2 (en) | 2006-12-12 |
WO1997036619A3 (en) | 1998-01-29 |
DE69729380T2 (de) | 2005-07-14 |
JP2004210796A (ja) | 2004-07-29 |
US20020034476A1 (en) | 2002-03-21 |
US20040156785A1 (en) | 2004-08-12 |
AU2544897A (en) | 1997-10-22 |
NZ331629A (en) | 2000-04-28 |
EP0907379B1 (en) | 2004-06-02 |
AU726914B2 (en) | 2000-11-23 |
IL125895A (en) | 2001-09-13 |
CA2247620A1 (en) | 1997-10-09 |
CN1215341A (zh) | 1999-04-28 |
US20060275216A1 (en) | 2006-12-07 |
DE69729380D1 (de) | 2004-07-08 |
NO319674B1 (no) | 2005-09-05 |
IL125895A0 (en) | 1999-04-11 |
KR20060025233A (ko) | 2006-03-20 |
IS4833A (is) | 1998-08-26 |
NO984543D0 (no) | 1998-09-29 |
IS2059B (is) | 2005-10-14 |
PT907379E (pt) | 2004-09-30 |
CN1108824C (zh) | 2003-05-21 |
US6709646B2 (en) | 2004-03-23 |
WO1997036619A2 (en) | 1997-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1016877A1 (en) | Bioactivated diagnostic imaging contrast agents. | |
NO20002380D0 (no) | Forbindelser for før-døden diagnose av Alzheimers sykdom og in vivo billeddannelse, samt forhindring av amyloid deponering | |
EP0994352A3 (en) | Contrast agent enhanced magnetic resonance imaging of myocardial tissue | |
CA2268324A1 (en) | Administrable compositions and methods for magnetic resonance imaging | |
YU6502A (sh) | Usmeravanje multimernih agenasa za dobijanje kontrasta pri dijagnostičkom snimanju putem multilokusnog vezivanja | |
CA2222974A1 (en) | Magnetic resonance imaging agents for the detection of physiological agents | |
AU4918896A (en) | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging | |
WO2001082976A3 (en) | Functional mri agents for cancer imaging | |
WO2002051301A3 (en) | Fullerene (c60)-based x-ray contrast agent for diagnostic imaging | |
WO1999025389A3 (en) | Magnetic resonance imaging agents for the detection of physiological agents | |
GEP20053423B (en) | Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits | |
HUP9900426A3 (en) | Amyloid binding azoderivatives, preparation thereof and use of these compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition | |
GB0130305D0 (en) | Compounds for imaging alzheimers disease | |
IL121084A0 (en) | Compositions and methods for diagnosis of tumors by X-ray imaging | |
AU4546996A (en) | Liposome suspensions as blood pool imaging contrast agents | |
EP0948361A4 (en) | MAGNETIC RESONANCE BLOOD POOL IMAGING AGENTS | |
AU5187696A (en) | Nanoparticulate diagnostic triiodo benzoate derivatives as x-ray contrast agents for blood pool and lymphatic system imaging | |
UA41932C2 (uk) | Засіб для ямр-томографії | |
IL133426A0 (en) | Compositions and methods for diagnosis of tumors by x-ray imaging | |
UA29125A (uk) | Спосіб діагностики розсіяного склерозу |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20080325 |